Dr. Reisa Sperling is a neurologist focused on the detection and treatment of Alzheimer’s disease, even before clinical symptoms are evident. She is the co-Principal Investigator, with Dr. Keith Johnson, of the Harvard Aging Brain Study in Boston. Her research uses neuroimaging and cognitive tests to understand the aging brain and the earliest changes associated with Alzheimer’s disease. Dr. Sperling is a Professor in Neurology at Harvard Medical School, Director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital, and Director of Neuroimaging for the Massachusetts ADRC at Massachusetts General Hospital. Dr. Sperling led the NIA-Alzheimer’s Association workgroup to develop guidelines for “Preclinical Alzheimer’s disease,” and currently serves on the Advisory Council of the National Institute on Aging. Dr. Sperling is also the Project Leader for the Anti-Amyloid Treatment in Asymptomatic AD (A4) study – a landmark secondary prevention trial in over 1000 clinically normal older individuals with PET amyloid imaging evidence of early Alzheimer’s disease pathology. Dr. Sperling is a 2015 awardee of the American Academy of Neurology Potamkin Prize, and was named one of the 2017 Most Disruptive Women to Watch in Healthcare.